A2 Refereed review article in a scientific journal
Nordic consensus document on Evolut FX+ transcatheter aortic valve implantation: optimizing index implantation and longer-term outcomes
Authors: Khokhar, Arif A.; Savontaus, Mikko; Al-Ani, Ahmed; Terkselsen, Christian Juhl; Bieliauskas, Gintautas; van der Heijden, Annemieke; Amin Azad, Alhasan Alhaj; James, Stefan; Russell, Kristoffer; De Backer, Ole
Publisher: Frontiers Media SA
Publication year: 2025
Journal: Frontiers in Cardiovascular Medicine
Article number: 1682714
Volume: 12
ISSN: 2297-055X
eISSN: 2297-055X
DOI: https://doi.org/10.3389/fcvm.2025.1682714
Publication's open availability at the time of reporting: Open Access
Publication channel's open availability : Open Access publication channel
Web address : https://doi.org/10.3389/fcvm.2025.1682714
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/505621844
Transcatheter aortic valve replacement (TAVI) is an established treatment strategy for patients with severe symptomatic aortic stenosis (AS). Multiple landmark randomized controlled trials have consistently demonstrated the safety, efficacy, and longer-term durability of the CoreValve/Evolut (Medtronic, MN, USA) transcatheter aortic valve (TAV) platform in treating severe AS. These findings have supported the expansion of TAVI to younger patients with longer life expectancy, in whom an optimized index valve implantation can significantly impact both acute procedural results and longer-term outcomes. In this technical narrative, we aim to describe how iterative changes in the latest-generation Evolut FX(+) TAV can be utilized to achieve an optimized index valve implantation.
Downloadable publication This is an electronic reprint of the original article. |  |
Funding information in the publication:
The author(s) declare that no financial support was received for the research and/or publication of this article.
